Ameparomo Capsules 250 mg Drug Use Investigation

NCT02680665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-12-09

Study results available
· View outcomes & findings →

Summary

This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.

Conditions

  • Intestinal Amebiasis

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
15 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-19
Primary Completion
2018-12-21
Completion
2018-12-21

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680665 on ClinicalTrials.gov